Financial Results - Biotricity Inc. reported financial results for the period ended December 31, 2025[5]. - The press release detailing the financial results was issued on February 11, 2026[5]. Company Classification - The company is not classified as an emerging growth company under the Securities Act[4]. - No securities are registered pursuant to Section 12(b) of the Act[3]. Reporting Information - The information in the report is not deemed "filed" under the Exchange Act[6]. - The report includes a press release as Exhibit 99.1[7]. - The report was signed by Chief Financial Officer S. John Ayanoglou on February 18, 2026[11].

Financial Data and Key Metrics Changes - For the third quarter of fiscal 2026, revenue increased by 10.2% to $4 million from $3.6 million in the prior year quarter [10] - Gross profit for the quarter totaled $3.2 million, up 17.6% from $2.8 million for the prior year period, with a gross profit percentage improvement to 81.5% from 76.4% [11] - EBITDA for the quarter was $280,000, corresponding to $0.01 on a per-share basis, marking the third consecutive quarter of positive EBITDA [14] Business Line Data and Key Metrics Changes - Recurring revenue reflects strong market adoption of the primary subscription model, driven by the popularity of FDA-cleared cardiac monitor devices, particularly the next-generation Biotres Pro [9] - Technology fees accounted for 91.2% of the quarter's total revenue, indicating strong customer retention and quality of support services [11] - Sales of BioCore Pro, the next-generation cardiac monitoring device, continued to expand, contributing to improved utilization and accelerating the path towards breakeven [7] Market Data and Key Metrics Changes - The digital health app user base grew from 4,500 to over 44,000 in two years, with an expanding network of over 2,500 providers supporting 400,000 patients annually [10] - The focus on atrial fibrillation as a primary contributor to strokes remains significant, with early intervention opportunities improving patient outcomes and potentially delivering healthcare cost savings [10] Company Strategy and Development Direction - The company is focused on transitioning from reactive care to proactive management in chronic care markets, particularly in cardiovascular disease [3][4] - Biotricity aims to expand its geographic footprint and is pursuing regulatory approvals internationally while maintaining a primary focus on U.S. market expansion [5][12] - The strategic initiatives and technological advancements are designed to position Biotricity for sustained growth and profitability in 2026 [8][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued revenue growth and the expectation of turning net income positive in the current year [18] - The company is excited about the prospects for 2026, anticipating sustained growth in the top line and improvements in operational efficiencies [16][18] Other Important Information - Operating expenses for the third quarter were $2.8 million, a decrease of 4.2% compared to the same period last year [12] - The net loss attributable to common stockholders for the quarter was $1.1 million, an improvement from $1.3 million in the prior year period [15] Q&A Session Summary - There were no questions during the Q&A session, and the conference concluded with management expressing excitement about future prospects [17][19]

Biotricity (OTCPK:BTCY) Q3 2026 Earnings call February 11, 2026 04:30 PM ET Speaker1Good afternoon, and welcome to Biotricity's third quarter fiscal 2026 financial results and business update conference call. Today's conference is being recorded. As a reminder, this is Biotricity's third quarter fiscal 2026, ended on December 31, 2025. So all figures presented for this period will reflect that end date. Earlier, Biotricity issued its earnings press release for the period, which highlighted financial and ope ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ to_______________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 (Registrant's Telephone Number, Including Area Code) Indicate by check whether the registrant: (1) has filed all reports required to be ...

REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing ...

Core Insights - Biotricity Inc. continues to demonstrate strong financial performance with positive EBITDA and ongoing revenue growth [1] - The company is set to host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11, 2026, at 4:30 PM ET [2] - Biotricity is focused on transforming the healthcare industry through innovative remote monitoring and diagnostic solutions [1][3] Financial Performance - The company has achieved a positive EBITDA, indicating improved operational efficiency and margin strength [1] - Continued growth in financial performance is highlighted, although specific revenue figures are not disclosed [1] Business Update Call - The upcoming call will feature remarks from Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, followed by a Q&A session for investors [1][2] - Investors can access the call via a toll-free number or through a webcast, with a replay available approximately three hours after the live event [2][3] Company Overview - Biotricity is dedicated to bridging gaps in remote monitoring and chronic care management, providing trusted solutions for preventive and personal care [3] - The company develops comprehensive remote health monitoring solutions for both medical and consumer markets [3]

Industry Overview - Healthcare information technology (IT) is attracting significant investor interest in 2025 due to the acceleration of digital transformation in the U.S. health system, with investments aimed at enhancing telehealth access, streamlining workflows, and improving chronic disease management [1][2] - The global healthcare IT market was valued at $663 billion in 2023 and is projected to grow to $1,834.3 billion by 2030, reflecting a compound annual growth rate (CAGR) of 15.8% from 2024 to 2030, with North America holding over 40% of the market share in 2023 [3] Investment Opportunities - Investors are focusing on companies that offer scalable technology with recurring revenue models, as several healthcare IT stocks have outperformed broader indices in 2025, driven by strong fundamentals and product expansion [4] - Notable U.S.-listed stocks include Hims & Hers Health, Inc. (HIMS), Biotricity, Inc. (BTCY), and Privia Health Group, Inc. (PRVA), all of which have seen year-to-date share price gains exceeding 20% [4][10] Company Highlights Hims & Hers Health, Inc. (HIMS) - HIMS has gained 44.9% in 2025, focusing on a consumer-centric telehealth platform that offers personalized treatment plans and wellness solutions across various health domains [6] - The company reported nearly $600 million in Q3 revenues, a 49% year-over-year increase, with a subscriber base growth of about 21% to approximately 2.5 million [7] - HIMS is expanding its services and has initiated a $250 million share repurchase program, indicating confidence in long-term value creation [8] Biotricity, Inc. (BTCY) - BTCY has risen 25.9% year-to-date, focusing on remote patient monitoring solutions that support chronic disease management, particularly in cardiac care [11] - The company is recognized as one of the fastest-growing companies in the Americas, with improved gross margins and progress toward profitability [12][13] - Key metrics to monitor include recurring revenue growth and margin expansion as the company broadens its clinical applications [14] Privia Health Group, Inc. (PRVA) - PRVA has achieved a 22.9% stock growth in 2025, with Q3 revenues up 32.5% to $580.4 million and operating income increasing nearly 150% [19] - The company emphasizes value-based care and has expanded geographically through acquisitions, raising its full-year guidance [20] - Analysts maintain a strong buy view on PRVA, with sales and earnings estimates for 2026 suggesting growth of 9.7% and 142.9%, respectively [21]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOTRICITY INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 3845 (Primary Standard Industrial Classification Code Number) 30-0983531 (I.R.S. Employer Identification Number) 203 Redwood Shores Parkway, Suite 600 Redwood City, CA 94065 (904) 496-0027 (Address, including zip code, and telephone n ...

Financial Results Announcement - Biotricity Inc. announced its financial results for the period ended September 30, 2025[5] - The press release detailing the financial results was issued on November 14, 2025[5] Company Classification - The company is not classified as an emerging growth company under the Securities Act[4] Filing Status - The financial results will not be deemed "filed" under the Securities Exchange Act of 1934[6] Report Signatory - The report was signed by Waqaas Al-Siddiq, the Chief Executive Officer of Biotricity Inc.[11]

Financial Performance - Biotricity Inc. reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.08, and an improvement from a loss of $0.07 per share a year ago, representing an earnings surprise of +62.50% [1] - The company posted revenues of $3.89 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.36%, but showing an increase from $3.27 million in the same quarter last year [2] Stock Performance - Biotricity shares have increased approximately 82.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 14.6% [3] - The current Zacks Rank for Biotricity is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $4.1 million, and for the current fiscal year, it is -$0.32 on revenues of $15.8 million [7] - The estimate revisions trend for Biotricity was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - Biotricity operates within the Zacks Medical Info Systems industry, which is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]